The Campaign for Sustainable Rx Pricing (CSRxP) Communications Director Lauren Blair today issued the following statement applauding the launch of the Coalition Against Patent Abuse, a new multi-stakeholder organization working to protect patients from Big Pharma’s patent abuses, and encourage more generic and biosimilar competition:
“Big Pharma knows how to game the patent system to block out competition and protect their profits. In fact, this strategy has been so successful that many drug makers have been able to maintain their monopolies for decades, driving up prices on the same medications without making significant improvements to the products patients need most.
“Just look at AbbVie, which has increased price of Humira, the world’s best-selling drug,12 times over the last five years, action the company has been able to take by continually filing new patents that prevent any competing drugs from coming to market.”
“This coalition will play a critical role in shining a light on the industry’s most monopolistic practices and proposing solutions that boost generic and biosimilar competition, creating more choice and lower drug prices for patients.”
CLICK HERE to watch CAPA’s launch event.
A recent series of studies conducted by Initiative for Medicines, Access, and Knowledge (I-MAK) found that of the top 12 grossing drugs in America, over 125 patent applications were filed and 71 were granted per drug. These patent applications attempted to block generic competition from entering the market by an average of 38 years, nearly double 20-year protection normally intended under U.S. patent laws. (“Overpatented, Overpriced: How Excessive Pharmaceutical Patenting Is Extending Monopolies And Driving Up Drug Price,” I-MAK, 8/18)
I-MAK also found: